Shingles vaccine to prevent dementia in Finland
Treatments studied
Part of Brain & nervous system, Infections, Mental health clinical trials.
This study tests whether the shingles vaccine can reduce the risk of developing dementia in adults 76 and older living in Finland. You would get the vaccine and then researchers will follow your health records for up to several years to see if it protects your brain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 76 years or older and live permanently in Finland.
- You have never received a shingles vaccine before.
- You have never been diagnosed with dementia, and you are not currently being checked for it.
- Your immune system is not severely weakened by a medical condition or medication.
- You do not live in a nursing home.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new shingles vaccine to see how well it prevents shingles in adults aged 40 and older. It aims to help those who have not had shingles recently or been vaccinated against it before.
This study tests a new vaccine to prevent shingles (a painful rash condition) in adults 50 and older. It checks how safe the vaccine is and how well it triggers the body's immune defense.
This trial is testing an experimental mRNA vaccine for preventing shingles. It aims to see if the vaccine is safe and triggers a good immune response in people aged 50 to 79.
This trial tests an experimental vaccine designed to prevent shingles (a painful rash caused by the varicella-zoster virus). It will help see if the vaccine is safe and triggers a good immune response in adults 40 and older.
This study tests an investigational vaccine (SYS6017) to see how well it works and if it's safe for adults 40 and older. The vaccine aims to prevent shingles, a painful rash caused by the same virus as chickenpox.
This trial tests a new investigational shingles vaccine to see if it is safe and produces an immune response in healthy adults 40 and older. Participating could help protect against shingles and its complications.
Hear when a new Herpes Zoster trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.